Beijing Beilu Pharmaceutical - Asset Resilience Ratio

Latest as of September 2025: 10.67%

Beijing Beilu Pharmaceutical (300016) has an Asset Resilience Ratio of 10.67% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥343.64 Million
≈ $50.28 Million USD Cash + Short-term Investments

Total Assets

CN¥3.22 Billion
≈ $471.45 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2005–2024)

This chart shows how Beijing Beilu Pharmaceutical's Asset Resilience Ratio has changed over time. Check 300016 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Beijing Beilu Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Beijing Beilu Pharmaceutical market cap and net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥343.64 Million 10.67%
Total Liquid Assets CN¥343.64 Million 10.67%

Asset Resilience Insights

  • Moderate Liquidity: Beijing Beilu Pharmaceutical has 10.67% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

Beijing Beilu Pharmaceutical Industry Peers by Asset Resilience Ratio

Compare Beijing Beilu Pharmaceutical's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Alkem Laboratories Limited
NSE:ALKEM
Drug Manufacturers - Specialty & Generic 31.91%
Beijing Tongrentang Co Ltd
SHG:600085
Drug Manufacturers - Specialty & Generic 0.50%
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
Drug Manufacturers - Specialty & Generic 28.06%
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
Drug Manufacturers - Specialty & Generic 4.97%
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
Drug Manufacturers - Specialty & Generic -2.56%
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
Drug Manufacturers - Specialty & Generic 24.59%
Zhejiang Medicine Co Ltd
SHG:600216
Drug Manufacturers - Specialty & Generic 1.85%
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
Drug Manufacturers - Specialty & Generic 3.47%

Annual Asset Resilience Ratio for Beijing Beilu Pharmaceutical (2005–2024)

The table below shows the annual Asset Resilience Ratio data for Beijing Beilu Pharmaceutical.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 11.78% CN¥350.77 Million
≈ $51.33 Million
CN¥2.98 Billion
≈ $435.71 Million
+12.39pp
2023-12-31 -0.61% CN¥-17.20 Million
≈ $-2.52 Million
CN¥2.82 Billion
≈ $412.57 Million
-0.08pp
2022-12-31 -0.53% CN¥-14.79 Million
≈ $-2.16 Million
CN¥2.82 Billion
≈ $412.00 Million
-0.15pp
2021-12-31 -0.38% CN¥-11.00 Million
≈ $-1.61 Million
CN¥2.90 Billion
≈ $424.78 Million
-0.13pp
2020-12-31 -0.25% CN¥-7.14 Million
≈ $-1.04 Million
CN¥2.85 Billion
≈ $416.69 Million
+0.21pp
2019-12-31 -0.46% CN¥-7.47 Million
≈ $-1.09 Million
CN¥1.62 Billion
≈ $237.62 Million
-0.41pp
2018-12-31 -0.05% CN¥-666.64K
≈ $-97.55K
CN¥1.29 Billion
≈ $188.58 Million
-5.80pp
2016-12-31 5.75% CN¥55.00 Million
≈ $8.05 Million
CN¥956.09 Million
≈ $139.91 Million
+4.63pp
2005-12-31 1.13% CN¥1.21 Million
≈ $177.06K
CN¥107.46 Million
≈ $15.72 Million
--
pp = percentage points

About Beijing Beilu Pharmaceutical

SHE:300016 China Drug Manufacturers - Specialty & Generic
Market Cap
$659.75 Million
CN¥4.51 Billion CNY
Market Cap Rank
#10776 Global
#2908 in China
Share Price
CN¥8.01
Change (1 day)
+2.04%
52-Week Range
CN¥7.23 - CN¥11.26
All Time High
CN¥27.25
About

Beijing Beilu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. The company provides contrast agents, such as gadopentetate meglumine injection, gadobutrol injection, and gadobenate meglumine injection for MRI contrast; and iohexol injection, iopamidol injection, and iodixanol injection for CT contrast, as well as glimepiride … Read more